ATI-2231 in Advanced Solid Tumor Malignancies
The purpose of this first-in-human study is to test ATI-2231 in advanced solid tumor malignancies with the goal of establishing the recommended Phase II dose of ATI-2231.
Advanced Solid Tumor|Advanced Solid Tumor Malignancies
DRUG: ATI-2231
Number of participants experiencing adverse events, -Graded per CTCAE v. 5.0, From baseline through 30 days after end of treatment (estimated to be 7 months)
Changes in ATI-2231 pharmacokinetics (PK) as measured by time to peak drug concentration (Tmax), Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, 30 hours, and 48 hours post dose cycle 1 day 1 (estimated to be 2 days)|Changes in ATI-2231 pharmacokinetics (PK) as measured by elimination rate constant, Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, 30 hours, and 48 hours post dose cycle 1 day 1 (estimated to be 2 days)|Changes in ATI-2231 pharmacokinetics (PK) as measured by apparent volume of distribution, Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, 30 hours, and 48 hours post dose cycle 1 day 1 (estimated to be 2 days)|Changes in ATI-2231 pharmacokinetics (PK) as measured by apparent clearance, Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, 30 hours, and 48 hours post dose cycle 1 day 1 (estimated to be 2 days)|Changes in ATI-2231 pharmacokinetics (PK) as measured by peak concentration (Cmax), Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, 30 hours, and 48 hours post dose cycle 1 day 1 (estimated to be 2 days)|Changes in ATI-2231 pharmacokinetics (PK) as measured by half-life (T1/2), Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, 30 hours, and 48 hours post dose cycle 1 (estimated to be 2 days)|Changes in ATI-2231 pharmacokinetics (PK) as measured by area under the curve (AUC0-24h), Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, and 24 hours post dose cycle 1 (estimated to be 1 day)|Changes in ATI-2231 pharmacokinetics (PK) as measured by area under the curve (AUC0-infinity), Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, 30 hours, and 48 hours post dose cycle 1 (estimated to be 2 days)|Changes in ATI-2231 pharmacokinetics (PK) as measured by area under the curve (AUC0-t), Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, 30 hours, and 48 hours post dose cycle 1 (estimated to be 2 days)|Changes in ATI-2231 pharmacokinetics (PK) as measured by peak concentration (Cmax), Pre-dose cycle 2 day 1 (each cycle is 21 days), 1 hour, 2 hours, 4 hours, 6 hours, and 10 hours post dose cycle 2 day 1 (estimated to be 10 hours)|Changes in ATI-2231 pharmacokinetics (PK) as measured by trough concentration, Pre-dose cycle 2 day 1 (each cycle is 21 days), 1 hour, 2 hours, 4 hours, 6 hours, and 10 hours post dose cycle 2 day 1 (estimated to be 10 hours)|Changes in ATI-2231 pharmacokinetics (PK) as measured by area under the curve (AUC0-t), Pre-dose cycle 2 day 1 (each cycle is 21 days), 1 hour, 2 hours, 4 hours, 6 hours, and 10 hours post dose cycle 2 day 1 (estimated to be 10 hours)|Changes in ATI-2231 pharmacokinetics (PK) as measured by time to peak drug concentration (Tmax), Pre-dose cycle 2 day 1 (each cycle is 21 days), 1 hour, 2 hours, 4 hours, 6 hours, and 10 hours post dose cycle 2 day 1 (estimated to be 10 hours)|ATI-2231 pharmacokinetics (PK) as measured by trough concentration, Cycle 3 day 1 (each cycle is 21 days)|ATI-2231 pharmacokinetics (PK) as measured by trough concentration, Cycle 4 day 1 (each cycle is 21 days)|ATI-2231 pharmacokinetics (PK) as measured by trough concentration, Cycle 5 day 1 (each cycle is 21 days)|ATI-2231 pharmacokinetics (PK) as measured by trough concentration, Cycle 6 day 1 (each cycle is 21 days)
The purpose of this first-in-human study is to test ATI-2231 in advanced solid tumor malignancies with the goal of establishing the recommended Phase II dose of ATI-2231.